Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
News|Webcasts|August 28, 2023
Using Open Source in Clinical Research Solutions
Author(s)IQVIA
Webinar Date/Time: Thursday, October 5th, 2023 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
Register for our latest webinar and discover opportunities utilizing open-source languages with IQVIA Data Flow Ecosystem that provide new patient touchpoints for accelerated trial development.
If you’re considering a more flexible and complimentary approach to SAS using open-source solutions IQVIA’s latest webinar can help you provide a new innovative framework to open up your trial development across programming and biostatistics.
Register Free:
Event overview
In an industry dominated by a traditional foundation centered around the SAS programming language and supporting platform offerings, IQVIA is investigating new opportunities to utilize open-source language offerings such as the R programming language.
Opportunities across the spectrum are being considered ranging from the flexibility allowed by open-source solutions, language agnostic tools, complimentary/supplementary solutions to SAS and application development using R Shiny frameworks.
Three key take-aways
- Outlining how IQVIA’s Data Flow Ecosystem provides new patient/client touchpoint solutions for programming across trials.
- Assessment of the R language as a supplement or complement to the SAS language opens up opportunities for improved validation independence, better situational solutions and resourcing flexibility.
- Application development using R and the R Shiny framework provides opportunities for targeted grassroots innovation with minimal IT support cost leading to larger scale ecosystem innovation.
Speakers:
Jim Beck
Director Statistical Programming
IQVIA
Jim has had a 21-year tenure with Quintiles / IQVIA Data Management, Biostatistics and IT organizations. He is currently Director of Data Flow & Standards team within the Biostatistics Innovation Group Implementation and governance of processes related to the flow of metadata and data as it moves from initial consumption through the Biostatistics workflow. He has experience spanning multiple TAs, including Psychiatry, Neurology, Respiratory. Jim also works with the implementation of standards and standardization for IQVIA and Sponsor Biostatistical libraries and processes including specifications, programming code & macros, submission packages, define.xml, etc.
Strategy team represents CDISC (SDTM, ADaM) Subject Matter Experts and Biostatistics (TLF, Define.XML, aCRF, SDRG, etc.) Subject Matter Experts partnering with sponsors and industry to establish new ways of working.
Ian Sanderson
Associate Director, Innovation Lead Biostatistics
IQVIA
Ian has over 12 years of clinical trial industry experience spanning a range of therapeutic areas including; Alzheimer's, Dementia, Schizophrenia, Chronic Pain, Oncology, Crohn's Disease and Diabetes. He joined IQVIA in Jun 2017 as a Programming Team Lead (PTL) for multiple studies before moving into an oversight role. During his time at IQVIA Ian's personal development has focused on supporting and developing innovation through Macros and Programming Processes group (MaPPs) and Bios Innovation Team. More recently he has move from direct study work into innovation full time and is currently the innovation lead for both Execution Manager and Risk-Based Validation (as well as supporting other innovation streams).
Register Free:
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.
In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5